Fennec Pharmaceuticals (TSE:FRX) Hits New 1-Year High – What’s Next?

Fennec Pharmaceuticals Inc. (TSE:FRX)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as C$15.48 and last traded at C$15.42, with a volume of 272 shares trading hands. The stock had previously closed at C$15.00.

Fennec Pharmaceuticals Stock Up 1.2%

The stock has a market capitalization of C$535.64 million, a price-to-earnings ratio of -53.17 and a beta of 3.52. The stock has a 50 day moving average price of C$11.83 and a 200 day moving average price of C$10.85.

Insider Activity at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov sold 9,747 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of C$13.23, for a total transaction of C$128,952.81. Following the completion of the transaction, the director owned 2,746,104 shares of the company’s stock, valued at approximately C$36,330,955.92. This trade represents a 0.35% decrease in their ownership of the stock. Also, Director Chris Anigeron Rallis sold 8,346 shares of Fennec Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of C$9.67, for a total transaction of C$80,705.82. Following the transaction, the director owned 61,314 shares in the company, valued at approximately C$592,906.38. This trade represents a 11.98% decrease in their position. 16.20% of the stock is owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.